U.S. markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
19.94+0.70 (+3.64%)
At close: 4:00PM EST
Sign in to post a message.
  • M
    MR
    I believe what we are seeing right now is the last ditch attempt of the shorts to try and get out before next week. The slide at the end of the day yesterday was an effort to kick in some stop loss orders that would have made sense given the rise and history of this stock. I think there will be a very strong Finnish today and Monday before earnings to try and clear out some shares. They have a lot to lose on this one with everything coming up. It will be nice to finally be rid of them soon.
  • T
    The real Onyxpig
    If there was an earnings leak, volume would have been a heck of a lot more than 1.2 million shares. Omidria sales will be solid and around $35 million IMO. The the old days, Omeros would spike $3-$4 and fall back $10. Maybe this time it will do the opposite🤗
  • M
    MR
    I did not see the forbes article until it was mentioned on this board. Thank you. It sounds like something Greg would write. The only thing missing in the article is the suggestion that OMER has the product ready to go to be put into use to save lives, reduce overall medial costs and improve the load at hospitals. As I have said before, there are 3 very large catalysts on the MC and SP at this time. 1). current Omidria sales - 13-15 dollars a share 700m MC. Will continue to add value with potential partnership. 2). FDA approval of Narso for TMA. $40 SP, 2.5b mc. 3). Covid application at a reduced cost to Government thru the I SPY program. $40 SP $2.5b MC. Also, helps quite a bit with the supply chain, cash flow and government will most likely put close to 1.0m billion in cash into the company for ramp up. So, this goes, to 65, then over 100 by the end of the July. 12m shares short - 20%. 7 day squeeze could start next week without news. Most likely situation will be, great CC coming up in two weeks, Covid application, FDA approval. Shorts see no way out, so look for big move next week without news...
    Bullish
  • U
    UpTech
    I assume everyone knows that CAO sale was according to a pre-arranged 10b5-1 trading plan? Funny nobody mentions that. When someone posts about that sale without mentioning that, you know what they are trying to do, don't you?
  • n
    noah
    Let's take this stock to a higher level. You need to find loose change and then rob your kid's piggy bank and own a few more shares of OMER. Do it for the children and the people who need the great products that OMER will provide in the future.
  • W
    WallStPirate
    From Forbes:

    Covid-19 is not influenza.

    Published studies from multiple leading international research laboratories make it clear that the SARS-CoV-2 virus causes a systemic disease we know as Covid-19, rather than a localized lung infection. The disease is transmitted throughout a patient’s body by the circulatory system. Along the way, the virus invades and injures the endothelial cells, which line all our blood vessels. Endothelial cell injury results in inflammation and leads to the generation of minute blood clots or thrombi (hyper-coagulation) that travel throughout the blood stream until they lodge in the smallest blood vessels (capillaries) where they restrict blood flow to virtually every organ system. This condition is known as thrombotic microangiopathy.

    The complement system is made up of about 25 proteins that work together to “complement” the action of antibodies in destroying bacteria. Complement proteins circulate in the blood in an inactive form. When the first protein in the complement series is activated— typically by antibody that has locked onto an antigen—it sets in motion a domino effect. Each component takes its turn in a precise chain of steps known as the complement cascade. The end product is a cylinder inserted into—and puncturing a hole in—the cell’s wall. With fluids and molecules flowing in and out, the cell swells and bursts.
    The complement system is made up of about 25 proteins that work together to “complement” the action ... [+] ORIGINAL WORK OF THE US FEDERAL GOVERNMENT - PUBLIC DOMAIN
    A primary driver of the inflammatory response to endothelial cell injury is the lectin pathway of complement, part of the body’s immune system. Activation of the lectin pathway in Covid-19 has been shown to cause an inflammatory cascade, including the “cytokine storm.” The consequence of lectin pathway activation and thrombotic microangiopathy in Covid-19 can be irreparable damage to the lungs, heart, kidney, liver, brain and other vital organs.

    Clinical and nonclinical data now show that lectin pathway inhibition by a therapeutic targeting the key enzyme in the lectin pathway mitigates the Covid-19 related inflammatory response and improves outcomes in critically ill Covid-19 patients.
  • K
    Khan
    3 vaccines approved in 1 year. Still not even trial for narsoplimab. In talks with government agencies for 7 months and nothing. Haha. Joke on you
  • V
    Van
    UBS investment bank initiated coverage BUY. 85% probability of NARSO approval by July 17. Pipeline advancements in 2021.
  • U
    UpTech
    2 Insiders just exercised and ACQUIRED stock. One sold, according to a pre-planned schedule. Why would insiders acquire stock? Only one reason.
  • T
    The real Onyxpig
    As we all speculate about Omidria revenues, I think all naysayers forget about “OMIDRIAssure”. All docs who were routinely using Omidria before the “blackout” period, continued to use Omidria as Greg was reimbursing them. Greg gets it ALL back, boys and girls. If you are a cataract surgeon and your drug of choice is pulled from the market, that’s one thing. They will continue to use Omidria as long as they are “assured” that they will be covered. “OMIDRIAssure” was set up to cover exactly what happened from 10/1 to 12/1. I believe we are in for a pleasant surprise, IMHO.
  • T
    The real Onyxpig
    There will be no dilution prior to FDA decision on Narsoplimab. Plenty of cash in the coffers from the August secondary. Back to the $20’s once yesterday’s dust devil subsides
  • E
    Emory
    Rule Number 1 - Bezos sold $3 Billion worth of stock 15 years ago at $350. hahahahahhaha
  • U
    UpTech
    Why did two insiders, BOD members including the CEO's brother, exercise and BUY shares of late?

    Hmmmmm.
  • b
    ben
    1,071k traded in the last hour and the price dropped $2.93 in just the last hour.
  • M
    MR
    Revenues and contribution margin as well as cash flow improvements should beat expectations on Monday. Updates on COVID and FDA approval should clarify for everyone next week. I expect it to continue up into report, then next week we should break all time highs.... Today and Friday are buying opportunities or short covering days before the really big run up. Today will close above 23.
    Bullish
  • J
    JohnnyB
    Early approval of NARSO, and stellar Omidria 4th qtr earnings. 30-40 pps right around the corner. Thanks Greg.
  • J
    JeffreyT
    Shares have gone up a lot, so it’s natural to wonder if we’re close to peaking, but when I look at ALXN market cap I feel like OMER could still go much higher. Our mechanism of action for similar pathologies appears to be superior. That’s not even factoring in it’s potential as a Covid treatment. I’m tightening my sphincter and holding on.
  • E
    Emory
    Monster volume, amazing the FAKE SELLERs can keep this down today ;)
  • b
    ben
    It took a month to go from $19. to $23 and they took it back in one day.
  • s
    syncnode
    02-16-2021 - Consonance Capital Management LP has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,058,505 shares of Omeros Corp. (US:OMER).

    This represents 9.99 percent ownership of the company.

    In their previous filing dated 2020-02-14, Consonance Capital Management LP had reported owning 3,195,796 shares, indicating an increase of 89.58 percent.